Phase i trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 5, 2012, Pages 319-324

  Weber, Donna M ^a   Graef, Thorsten ^b   Hussein, Mohamad ^c   Sobecks, Ronald M ^d   Schiller, Gary J ^e   Lupinacci, Lisa ^b   Hardwick, James S ^b   Jagannath, Sundar ^f,g  

^a UNIVERSITY OF TEXAS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; HDAC; HDAC inhibitor; Proteasome inhibitor; Suberoylanilide hydroxamic acid (SAHA); Synergistic

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE; VORINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; EPIPHORA; FATIGUE; FEMALE; FEVER; HEMATOTHORAX; HIP PAIN; HUMAN; HYPERMAGNESEMIA; LEG PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; REFRACTORY PERIOD; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE;

EID: 84867422068     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.07.007     Document Type: Article

References (24)

1. American Cancer Society Cancer Facts and Figures 2008 2008 American Cancer Society Atlanta, GA
2. M. Dimopoulos, A. Spencer, M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2007 2123 2132
3. S.V. Rajkumar, S. Hayman, M.A. Gertz Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319 4323
4. P.G. Richardson, B. Barlogie, J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
5. P.G. Richardson, P. Sonneveld, M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
6. S. Singhal, J. Mehta, R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
7. D. Weber, K. Rankin, M. Gavino Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
8. D.M. Weber, C. Chen, R. Niesvizky Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2007 2133 2142
9. C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A 101 2004 540 545
10. N. Mitsiades, C.S. Mitsiades, P.G. Richardson Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 2003 4055 4062
11. B.D. Strahl, C.D. Allis The language of covalent histone modifications Nature 403 2000 41 45
12. P. Richardson, C. Mitsiades, K. Colson Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 2008 502 507
13. S.T. Nawrocki, J.S. Carew, M.S. Pino Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Res 66 2006 3773 3781
14. X.Y. Pei, Y. Dai, S. Grant Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 2004 3839 3852
15. J. Bladé, D. Samson, D. Reece Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 1998 1115 1123
16. Y.W. Huang, A. Hamilton, O.J. Arnuk Current drug therapy for multiple myeloma Drugs 57 1999 485 506
17. Proposed guidelines for protocol studies: I. Introduction II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia Cancer Chemother Rep 3 4 1973 141 173
18. M. Duvic, R. Talpur, X. Ni Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 2007 31 39
19. O.A. O'Connor, M.L. Heaney, L. Schwartz Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 2006 166 173
20. E.A. Olsen, Y.H. Kim, T.M. Kuzel Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 3109 3115
21. A. Badros, A.M. Burger, S. Philip Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 2009 5250 5257
22. A. Badros, S. Philip, R. Niesvizky Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts) [Abstract] Blood 110 2007 1168
23. D. Weber, A.Z. Badros, S. Jagannath Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience [Abstract] Blood 112 2008 871
24. P.N. Munster, E.H. Rubin, S. Van Belle A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer Clin Cancer Res 15 2009 7077 7084